First-in-human testing of 4A10 for relapsed or hard-to-treat ALL and lymphoblastic lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, first-in-human study of 4A10, a CD127-targeting antibody. Participants with relapsed or refractory ALL or lymphoblastic lymphoma receive weekly IV infusions of 4A10 to determine safety, dosing, and pharmacokinetics, while monitoring for early signs of activity. The study uses a cautious dose-escalation approach in small cohorts, with close observation during the initial treatment cycle (about 4–6 weeks). Primary goals focus on safety and identifying a recommended dose, with exploratory assessments of anti-leukemic effects.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Confirmed diagnosis of T/B-ALL or T/B-LL
2. Relapsed or refractory disease without curative options
3. Adequate organ function and performance status

Key Exclusion Criteria:

1. Patients with CNS3 disease
2. Patients with DNA fragility syndromes (e.g., Fanconi, Bloom), trisomy 21 (Down Syndrome)
3. Prior exposure to anti-CD127 therapies
4. Uncontrolled infections

Where it's running

• Children's Hospital Colorado
  Aurora, Colorado, United States Recruiting
• Riley Children's Hosptial
  Indianapolis, Indiana, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting
• Cook Children's Medical Center
  Fort Worth, Texas, United States Recruiting
• Texas Children's Hospital
  Houston, Texas, United States Recruiting
• Cincinnati Children's Hospital Medical Center
  Cincinnati, Ohio, United States Not yet recruiting

Study contacts

• Study coordinator: Shibani M Kudchadkar, MD
• Email: skudchadkar@allterum.com
• Phone: 15153439875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Child and Young Adult (CAYA) Cancer Outcomes Review

  This project looks at past treatment results to see what affects outcomes for children and young adults (ages 0–21) with leukemia and other cancers treated at participating centers in low- and middle-income countries.

  Recruiting at 5 sites Resonance, Inc. · Yerevan and 6 other locations · NCT07246213

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes

  This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.

  Recruiting Resonance, Inc. · Yerevan and 5 other locations · NCT07632014

• Plasma cell-free DNA in children with ALL to help monitor disease

  This study tests whether measuring tumor DNA in blood can help monitor acute lymphoblastic leukemia in kids without needing frequent bone-marrow tests.

  Recruiting at 2 sites Assistance Publique - Hôpitaux de Paris · Paris and 1 other locations · NCT07483476

• Laughter and fun yoga to ease chemotherapy pain in children

  This tests whether a home-based program of laughter and kid-friendly yoga can lower pain in children aged 2–10 who are receiving chemotherapy for acute lymphoblastic leukemia.

  Recruiting Beirut Arab University · Sidon · NCT07327138

• Tracking and predicting chemotherapy-related nerve damage in children with acute lymphoblastic leukemia

  Researchers will track how vincristine-related nerve damage develops over time in children (ages 8–17) with acute lymphoblastic leukemia and try to identify factors that predict different symptom patterns.

  Recruiting at 3 sites The Hong Kong Polytechnic University · Zhengzhou, Henan and 2 other locations · NCT07326930

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.